Compare BIO & DPZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | DPZ |
|---|---|---|
| Founded | 1952 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Food Distributors |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 11.6B |
| IPO Year | 1994 | 2004 |
| Metric | BIO | DPZ |
|---|---|---|
| Price | $364.61 | $310.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 30 |
| Target Price | $328.33 | ★ $373.15 |
| AVG Volume (30 Days) | 256.4K | ★ 720.5K |
| Earning Date | 10-29-2026 | 10-13-2026 |
| Dividend Yield | N/A | ★ 2.57% |
| EPS Growth | ★ 142.61 | 5.27 |
| EPS | N/A | ★ 8.21 |
| Revenue | $2,583,200,000.00 | ★ $4,939,994,000.00 |
| Revenue This Year | N/A | $4.94 |
| Revenue Next Year | $2.13 | $2.28 |
| P/E Ratio | ★ N/A | $37.64 |
| Revenue Growth | 0.65 | ★ 4.96 |
| 52 Week Low | $236.73 | $282.00 |
| 52 Week High | $396.23 | $442.35 |
| Indicator | BIO | DPZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 53.67 |
| Support Level | $358.85 | $297.56 |
| Resistance Level | $392.81 | $322.12 |
| Average True Range (ATR) | 12.52 | 7.15 |
| MACD | -2.22 | 3.21 |
| Stochastic Oscillator | 30.27 | 90.10 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Domino's is the world's largest pizza chain, surpassing $20 billion in system sales with over 22,100 stores across more than 90 markets at the end of 2025. Around 33% of its units are in the US. The business is 99% franchised. Domino's operates through three segments: supply chain (60% of revenue), US stores (33%), and international franchises (7%). The firm generates the bulk of its revenue by supplying food to stores in the US and Canada through a vertically integrated network of 25 manufacturing and supply chain facilities, which primarily produce and distribute dough, and collecting brand royalties and marketing fees from franchisees. Domino's also generates revenue from sales at company-owned stores.